Cargando…

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients

BACKGROUND: Sequential treatment with different generations of anaplastic lymphoma kinase (ALK) inhibitors have been widely applied to ALK-positive lung cancer; however, resistance mutations inevitably developed. Further characterization of ALK resistance mutations may provide key guidance to subseq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, G., Zhang, X., Zhang, M., Wang, Q., Chen, X., Yu, R., Bao, H., Liu, J., Wu, X., Shao, Y., Liang, B., Lu, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818928/ https://www.ncbi.nlm.nih.gov/pubmed/35123209 http://dx.doi.org/10.1016/j.esmoop.2021.100337

Ejemplares similares

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions
por: Zhu, You‐cai, et al.
Publicado: (2018)

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
por: Gibson, Amanda J.W., et al.
Publicado: (2021)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
por: Yang, Dafu, et al.
Publicado: (2021)

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
por: Nong, Jingying, et al.
Publicado: (2018)

Cuproptosis Depicts Immunophenotype and Predicts Immunotherapy Response in Lung Adenocarcinoma
por: Zhou, Wolong, et al.
Publicado: (2023)

Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis
por: Zhang, S, et al.
Publicado: (2014)

Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States
por: Burge, R. T., et al.
Publicado: (2016)

Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma
por: Rodić, Nemanja, et al.
Publicado: (2015)

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Wang, Michelle, et al.
Publicado: (2023)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
por: Nong, Jingying, et al.
Publicado: (2019)

Real-World LEAP Implementation
por: Koplin, Jennifer J., et al.
Publicado: (2022)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC
por: Wu, Jun, et al.
Publicado: (2022)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
por: Huang, Jie, et al.
Publicado: (2022)

The clonal evolution of metastatic colorectal cancer
por: Dang, Ha X., et al.
Publicado: (2020)

COUP-TFII regulates metastasis of colorectal adenocarcinoma cells by modulating Snail1
por: Bao, Y, et al.
Publicado: (2014)

Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes
por: Yao, Y., et al.
Publicado: (2022)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review
por: Wu, Yonghui, et al.
Publicado: (2021)

Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)
por: Baxter, Mark A., et al.
Publicado: (2021)

RanDepict: Random chemical structure depiction generator
por: Brinkhaus, Henning Otto, et al.
Publicado: (2022)

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
por: Angeles, Arlou Kristina, et al.
Publicado: (2023)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Oulhen, Marianne, et al.
Publicado: (2021)

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
por: Ma, Lin, et al.
Publicado: (2022)

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
por: Yeh, Paul, et al.
Publicado: (2017)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Circulating Cell-Free DNA Reflects the Clonal Evolution of Breast Cancer Tumors
por: Kujala, Jouni, et al.
Publicado: (2022)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8qd2ti8m476hhfoamt3tqbribt